Holland & Barrett International, an English health and wellness retailer, launched Vitaboost Levagen, an effervescent with Gencor’s Levagen PEA.
Holland & Barrett International, an English health and wellness retailer, launched Vitaboost Levagen, an effervescent with Gencor’s (Irvine, CA) Levagen PEA. It is formulated with a non-hemp CBD alternative, palmitoylethanolamide (PEA) that includes Lipisperse, a delivery system that increases the bioavailability and functionality of the ingredient. This is the second Gencor + Pharmako partnered product launched by Holland & Barrett.
“PEA was first identified in the 1950s as a potent anti-inflammatory, and today, Gencor has extensively studied its safety and efficacy for a variety of health conditions and as a CBD alternative,” said Chase Shryoc, VP of sales and business development at Gencor, in a press release. “PEA is the next generation of anti-inflammatory analgesics.”
Mariko Hill, product development executive at Gencor, said in a press release: “Although biogenetically different, CBD and PEA share a remarkable series of pharmacological similarities. Published studies have shown PEA to be effective in joint health, sports recovery, and sleep.”
Hill said the use of CBD and NSAIDS are an issue in sports. As such, PEA offers an alternative for athletes who are regularly tested for WADA-banned substances. "By working with numerous elite teams in the United Kingdom, we gain practical insights into the use of Levagen+ in recovery, injury, and trauma-based protocols" Hill added.